US Firm of Zydus Cadilla Receives Final Approval To Market Roflumilast Tablets
On Monday, 14th February 2022, Cadilla Healthcare Ltd said that, its US arm Zydus Pharmaceuticals Inc. has now received the final approval from the US FDA for the purpose marketing the company’s generic version of the Roflumilast tablets having the strength of 500 mcg that has been initiated for the purpose of decreasing the risk […]
Continue Reading